Latest news with #MattJones
News.com.au
5 days ago
- Entertainment
- News.com.au
Stars of cult TV show unrecognisable at their mini-reunion
Breaking Bad fans have been sent into a frenzy following a reunion by three of its stars, 10 years after the finale aired. Matt Jones, Charles Baker and Rodney Rush - better known as Badger, Skinny Pete and Combo, respectively - popped up on social media over the weekend after getting together for a meet and greet at the Breaking Bad store in Albuquerque. Baker posted an album of the event on Instagram, captioning it: 'Great times were had by all at the Breaking Bad store this weekend! Thank you all for being there.' A series of pictures was also posted on social media by talent manager Ben Brucato, who had helped arrange the fan experience. 'I had a great time bringing my good friends [Charles Baker, Matt Jones and Rodney Rush] to the first ever Skinny Pete, Badger and Combo reunion!' the Blunt Management founder wrote alongside a series of pictures of the trio. He went on to thank store staff for helping put on the 'amazing event'. Fans were delighted to see the cast back together, with one begging in the comments section: 'Let them have their own show already.' 'You three are my heroes!' added another. 'That's it, I'm watching Breaking Bad again,' one fan wrote. Breaking Bad, which premiered in 2008 and wrapped up in 2013, is widely considered one of the best television shows of all time. Starring Bryan Cranston as Walter White and Aaron Paul as Jesse Pinkman, it received critical acclaim for its performances and storytelling.
South Wales Argus
7 days ago
- Business
- South Wales Argus
Monmouthshire Upcycle celebrates ten years in Chepstow
Chepstow is home to a vibrant upcycling initiative led by Monmouthshire Upcycle, a charitable project operated by the Forest Upcycling Project. Located at Station Yard Industrial Estate, next to the town's railway station, the site is an Aladdin's cave,not just of trinkets and bric-a-brac, but of solid furniture and practical goods. The busy hub runs vans for free removals of unwanted household furniture and offers affordable moving services. The reuse facility transforms donated items such as furniture, appliances, books, and more, into affordable goods for the community. It reduces waste while providing employment and training opportunities for those in need of a new start, work experience or just people with time to spare who want to help build and help communities. Speaking about the project's vision, founder Matt Jones said: 'We believe in second chances, not just for furniture, but for people and futures.' Locals can donate unwanted items or purchase refurbished ones at a fraction of the original cost. From wardrobes and lamps to kitchen tables and baby goods, the selection is wide-ranging and constantly evolving. Delivery services make sustainable living even more accessible. Mechanic led police on 'erratic' high-speed chase and stole petrol from garages 'Pioneering' charity founder steps down after more than 30 years of involvement Beyond retail, Chepstow's upcycling efforts promote circular economy values. The project's expansion reflects growing demand and community support, proving that sustainability and compassion go hand in hand. As Matt puts it: 'The more money we make, the more people we can employ.' Staff and volunteers are a vibrant, creative bunch. The on-site café hosts a Repair Café on the first Friday of each month, where locals bring broken items and volunteers help fix them, keeping goods out of landfill and building connections. At the heart of the café is Natalia Lutiaenko, a Ukrainian refugee from Odessa who's been in the UK for three years. She's managed the café for 18 months and also works in a local school. With fellow Ukrainian Liliya Onopa, Natalia now serves traditional dishes like borscht, plov, varenyky, and holubtsi on-site. She jokes: 'All you need to know, pre-Google, is don't eat borscht while wearing a white top.' She loves British humour—especially Philomena Cunk—and fondly recalls how warmly she and her children were welcomed by a British family and the happy way of life here. Joining them is retired teacher and ceramicist Mariam Eastwood: 'I retired to become my late mother's carer. As a neurodiverse person, there was no pressure here—it was so welcoming. I was dealing with grief, and this place helped. After that, I was asked if I wanted a job' What began in Chepstow has now grown into a cross-border concern, with outlets in Cwmbran, Cinderford, and Swindon.
Otago Daily Times
10-07-2025
- Otago Daily Times
Dunedin bus fire deliberately lit
The house bus front and driver's side. PHOTO: NZ POLICE A fire investigator has ruled a bus fire on a residential street in Dunedin was arson. Early on November 14, a house bus parked in Maitland St, Dunedin, burst into flames. Fire and Emergency New Zealand investigator Matt Jones, along with the police criminal investigation branch and a police photographer, investigated due to the "suspicious nature" of the fire. He ultimately determined it was deliberately lit. Mr Jones said the fire was caused "by persons unknown and the ignition source was either taken away or consumed in the fire". "Fire patterns within the wheel arch space area also supported a hypothesis that a fire was started with an ignition source that could not be identified." The inside of the bus had almost no fire damage apart from a storage area below seats on the passenger side, Mr Jones said. The bus, a 1989 Mitsubishi Rosa camper, had not been used for some time. Electrical, gas, wiring and mechanical problems were quickly ruled out. "Three hypotheses were developed from the information and evidence collected during the scene examination. "The separate hypotheses were researched and tested against the fire patterns and physical evidence found at the scene. "The results from the testing eliminated two hypothesis as causing the fire."
Otago Daily Times
10-07-2025
- Otago Daily Times
Bus fire arson
The house bus front and driver's side. PHOTO: NZ POLICE A fire investigator has ruled a bus fire on a residential street in Dunedin was arson. Early on November 14, a house bus parked in Maitland St, Dunedin, burst into flames. Fire and Emergency New Zealand investigator Matt Jones, along with the police criminal investigation branch and a police photographer, investigated due to the "suspicious nature" of the fire. He ultimately determined it was deliberately lit. Mr Jones said the fire was caused "by persons unknown and the ignition source was either taken away or consumed in the fire". "Fire patterns within the wheel arch space area also supported a hypothesis that a fire was started with an ignition source that could not be identified." The inside of the bus had almost no fire damage apart from a storage area below seats on the passenger side, Mr Jones said. The bus, a 1989 Mitsubishi Rosa camper, had not been used for some time. Electrical, gas, wiring and mechanical problems were quickly ruled out. "Three hypotheses were developed from the information and evidence collected during the scene examination. "The separate hypotheses were researched and tested against the fire patterns and physical evidence found at the scene. "The results from the testing eliminated two hypothesis as causing the fire."
Yahoo
07-07-2025
- Health
- Yahoo
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI Data Being Presented at the 35th Annual International Cannabinoid Research Society Symposium SOLANA BEACH, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced the presentation of compelling new preclinical data on its Cannabidiol (CBD) and Tetramethylpyrazine (TMP) cocrystal drug candidate, ART12.11, at the 35th Annual International Cannabinoid Research Society (ICRS) Symposium, taking place July 6–10 in Bloomington, Indiana. The poster, titled 'ART12.11, A Novel Cannabidiol:Tetramethylpyrazine Cocrystal, Alleviates Stress-Induced Depressive Symptoms,' is being presented today by Matt Jones, a scientist working in the laboratory of Professor Steven Laviolette at the University of Western Ontario, Canada. The data highlight ART12.11's unique dual-action profile in improving depression-related behaviors in animals and reversing cognitive deficits associated with chronic stress. These are key differentiators that position ART12.11 as a potential next-generation treatment candidate in the multi-billion-dollar antidepressant market. Highlights: Robust Antidepressant-like Effects: A 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress. The data with ART12.11 demonstrated efficacy on par with sertraline (Zoloft), a leading selective serotonin reuptake inhibitor (SSRI). Restoration of Hedonic and Social Behaviors: Like sertraline, ART12.11 improved sucrose preference and social motivation, which are established behavioral markers of depressive-like states, to near-baseline levels. Superior Cognitive Restoration: Unlike sertraline, ART12.11 reversed stress-induced deficits in both spatial and short-term memory without negatively impacting social memory. Differentiated Therapeutic Profile: These findings underscore ART12.11's potential as a highly differentiated candidate for treating depression and anxiety, especially in patients where cognitive dysfunction occurs, which is a known limitation of existing SSRI therapies. 'Our latest behavioral studies suggest that the cocrystal holds strong potential as a novel antidepressant. In a stressed rodent model, ART12.11 significantly restored key depression-related behaviors to baseline levels. The ability to experience pleasure and social motivation with ART12.11 were comparable to the effects of the established antidepressant sertraline. Notably, ART12.11 also reversed stress-induced cognitive impairments, which is an area where sertraline was not as effective,' said Matt Jones, the lead researcher of this work at the University of Western Ontario. Prior preclinical research studies in animals with ART12.11 demonstrated greater behavioral and pharmacokinetic results compared to CBD or Epidiolex. These new findings observed in Dr. Laviolette's laboratory are from the first preclinical study that compared ART12.11 to a leading SSRI. 'Although strong antidepressant effects were noted with ART12.11 in prior studies, we are especially encouraged by these comparative findings,' said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. 'We believe ART12.11 has the potential to meet a critical need in the mental health landscape by delivering both mood-lifting and cognitive benefits. which could set ART12.11 apart from existing antidepressants.' About ART12.11ART12.11 is Artelo's wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Superior pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The US issued composition of matter patent for ART12.11 is enforceable until December 10, 2038 and has now been granted or validated in 19 additional countries. About Artelo BiosciencesArtelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. About the International Cannabinoid Research SocietyThe International Cannabinoid Research Society (ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. The ICRS Symposium is being held July 6-10, 2025 in Bloomington, IN. Interested parties may follow @ICRS_Society on X. Forward-Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company's future investment policy of its excess capital, product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management's current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, 'expect,' 'anticipate,' 'intend,' 'plan,' 'believe,' 'estimate,' 'potential,' 'predict,' 'project,' 'should,' 'would' and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company's filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
